Plasma miR-141-3p as a Potential Diagnostic Biomarker for Early Breast Cancer and a Functional Regulator with Tumor-Suppressive Effects in Luminal A Breast Cancer Cells.

Q2 Medicine

Asian Pacific Journal of Cancer Prevention Pub Date : 2026-09-01 DOI:10.31557/APJCP.2026.27.9.3227

Thuy Thi Chung Duong, Thanh Thi Ngoc Nguyen, Luan Huu Huynh, Nga Thi Nguyen, Hue Thi Nguyen

{"title":"Plasma miR-141-3p as a Potential Diagnostic Biomarker for Early Breast Cancer and a Functional Regulator with Tumor-Suppressive Effects in Luminal A Breast Cancer Cells.","authors":"Thuy Thi Chung Duong, Thanh Thi Ngoc Nguyen, Luan Huu Huynh, Nga Thi Nguyen, Hue Thi Nguyen","doi":"10.31557/APJCP.2026.27.9.3227","DOIUrl":null,"url":null,"abstract":"Objective: Breast cancer (BC) remains the most common malignancy in women worldwide, highlighting the need for reliable non-invasive biomarkers for early detection. miR-141-3p, a member of the miR-200 family, has shown context-dependent roles in tumorigenesis, but its diagnostic specificity and clinical relevance in the plasma of patients with BC remain incompletely understood. Therefore, this study aimed to assess the diagnostic potential and functional role of miR-141-3p in BC.Methods: Plasma miR-141-3p levels were quantified in breast cancer patients and healthy controls using RT-qPCR. Diagnostic capacity was evaluated via receiver‑operating characteristic (ROC) analysis. Associations between circulating miR-141-3p expression and BC risk were assessed using odds ratios (ORs). In vitro functional assays in MCF‑7 cells (miR‑141‑3p overexpression) examined effects on proliferation, migration, and regulation of target genes.Results: Circulating miR-141-3p was significantly upregulated in BC patients. ROC analysis yielded an AUC of 0.877 (95% CI: 0.782-0.971), demonstrating good diagnostic performance. No statistically significant stage-dependent difference was observed, suggesting that circulating miR-141-3p dysregulation may not simply reflect tumour burden. In vitro, miR‑141‑3p overexpression suppressed MCF‑7 cell proliferation and migration and reduced expression of EMT‑associated markers. Furthermore, strong inverse correlations were observed between miR‑141‑3p levels and its predicted oncogenic targets.Conclusion: Circulating miR‑141‑3p shows promise as a non‑invasive biomarker for BC detection and risk discrimination, although its specificity as a stand-alone marker may be limited. Its in vitro effects on proliferation, migration, and EMT markers indicate potential functional relevance. Further validation in larger cohorts and through in vivo studies is warranted.","PeriodicalId":55451,"journal":{"name":"Asian Pacific Journal of Cancer Prevention","volume":"27 9","pages":"3227-3235"},"PeriodicalIF":0.0000,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Asian Pacific Journal of Cancer Prevention","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.31557/APJCP.2026.27.9.3227","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: Breast cancer (BC) remains the most common malignancy in women worldwide, highlighting the need for reliable non-invasive biomarkers for early detection. miR-141-3p, a member of the miR-200 family, has shown context-dependent roles in tumorigenesis, but its diagnostic specificity and clinical relevance in the plasma of patients with BC remain incompletely understood. Therefore, this study aimed to assess the diagnostic potential and functional role of miR-141-3p in BC.

Methods: Plasma miR-141-3p levels were quantified in breast cancer patients and healthy controls using RT-qPCR. Diagnostic capacity was evaluated via receiver‑operating characteristic (ROC) analysis. Associations between circulating miR-141-3p expression and BC risk were assessed using odds ratios (ORs). In vitro functional assays in MCF‑7 cells (miR‑141‑3p overexpression) examined effects on proliferation, migration, and regulation of target genes.

Results: Circulating miR-141-3p was significantly upregulated in BC patients. ROC analysis yielded an AUC of 0.877 (95% CI: 0.782-0.971), demonstrating good diagnostic performance. No statistically significant stage-dependent difference was observed, suggesting that circulating miR-141-3p dysregulation may not simply reflect tumour burden. In vitro, miR‑141‑3p overexpression suppressed MCF‑7 cell proliferation and migration and reduced expression of EMT‑associated markers. Furthermore, strong inverse correlations were observed between miR‑141‑3p levels and its predicted oncogenic targets.

Conclusion: Circulating miR‑141‑3p shows promise as a non‑invasive biomarker for BC detection and risk discrimination, although its specificity as a stand-alone marker may be limited. Its in vitro effects on proliferation, migration, and EMT markers indicate potential functional relevance. Further validation in larger cohorts and through in vivo studies is warranted.

查看原文本刊更多论文

血浆miR-141-3p作为早期乳腺癌的潜在诊断生物标志物和在腔a乳腺癌细胞中具有肿瘤抑制作用的功能调节剂

目的：乳腺癌（BC）仍然是世界范围内女性最常见的恶性肿瘤，强调需要可靠的非侵入性生物标志物进行早期检测。miR-141-3p是miR-200家族的一员，在肿瘤发生中显示出环境依赖性作用，但其在BC患者血浆中的诊断特异性和临床相关性仍不完全清楚。因此，本研究旨在评估miR-141-3p在BC中的诊断潜力和功能作用。方法：采用RT-qPCR方法定量检测乳腺癌患者和健康对照组血浆miR-141-3p水平。通过受试者工作特征（ROC）分析评估诊断能力。使用比值比（ORs）评估循环miR-141-3p表达与BC风险之间的关系。MCF - 7细胞（miR - 141 - 3p过表达）的体外功能检测检测了其对靶基因增殖、迁移和调控的影响。结果：循环miR-141-3p在BC患者中显著上调。ROC分析显示AUC为0.877 (95% CI: 0.782-0.971)，具有良好的诊断效果。未观察到有统计学意义的阶段依赖性差异，提示循环miR-141-3p失调可能不仅仅反映肿瘤负担。在体外，miR - 141 - 3p过表达抑制了MCF - 7细胞的增殖和迁移，并降低了EMT相关标志物的表达。此外，miR - 141 - 3p水平与其预测的致癌靶点之间存在很强的负相关。结论：尽管miR - 141 - 3p作为一种独立标志物的特异性可能有限，但循环miR - 141 - 3p有望作为一种非侵入性的BC检测和风险区分生物标志物。它在体外对增殖、迁移和EMT标志物的影响表明了潜在的功能相关性。需要在更大的队列和体内研究中进一步验证。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Asian Pacific Journal of Cancer Prevention 医学-肿瘤学

CiteScore

2.80

自引率

0.00%

发文量

779

审稿时长

3 months

期刊介绍： Cancer is a very complex disease. While many aspects of carcinoge-nesis and oncogenesis are known, cancer control and prevention at the community level is however still in its infancy. Much more work needs to be done and many more steps need to be taken before effective strategies are developed. The multidisciplinary approaches and efforts to understand and control cancer in an effective and efficient manner, require highly trained scientists in all branches of the cancer sciences, from cellular and molecular aspects to patient care and palliation. The Asia Pacific Organization for Cancer Prevention (APOCP) and its official publication, the Asia Pacific Journal of Cancer Prevention (APJCP), have served the community of cancer scientists very well and intends to continue to serve in this capacity to the best of its abilities. One of the objectives of the APOCP is to provide all relevant and current scientific information on the whole spectrum of cancer sciences. They aim to do this by providing a forum for communication and propagation of original and innovative research findings that have relevance to understanding the etiology, progression, treatment, and survival of patients, through their journal. The APJCP with its distinguished, diverse, and Asia-wide team of editors, reviewers, and readers, ensure the highest standards of research communication within the cancer sciences community across Asia as well as globally. The APJCP publishes original research results under the following categories: -Epidemiology, detection and screening. -Cellular research and bio-markers. -Identification of bio-targets and agents with novel mechanisms of action. -Optimal clinical use of existing anti-cancer agents, including combination therapies. -Radiation and surgery. -Palliative care. -Patient adherence, quality of life, satisfaction. -Health economic evaluations.